AstraZeneca Canada Inc. has introduced a support program designed to take cost out of the equation in the patient’s choice between Nexium tablets and a generic esomeprazole product.
Eosinophilic esophagitis (EE) has emerged as a “new” inflammatory condition of note, one that has been diagnosed with increased frequency in both children and adults throughout the world.